ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Arch Biopartners Inc

Arch Biopartners Inc (ARCH)

2,00
0,06
(3,09%)
Fermé 04 Janvier 10:00PM

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

Dernier
2,00
Prix Achat
2,00
Prix Vente
2,03
Volume échangé
24 466
1,94 Fourchette du Jour 2,01
1,36 Plage de 52 semaines 2,56
Cap du marché
Clôture Veille
1,94
Ouverture
1,97
Dernière Transaction
300
@
2
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
17 142
Actions en circulation
62 598 000
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-37,66
Bénéfice par action (BPA)
-0,05
Chiffre d'affairess
1,98M
Bénéfice net
-3,33M

À propos de Arch Biopartners Inc

Secteur
Coml Physical, Biologcl Resh
Industrie
Advertising Agencies
Siège social
Toronto, Ontario, Can
Fondé
2010
Arch Biopartners Inc est coté dans le secteur Coml Physical, Biologcl Resh de la TSX Venture Exchange avec le ticker ARCH. Le dernier cours de clôture d'Arch Biopartners était de $1,94. Au cours de la dernière année, les actions de Arch Biopartners ont été négociées dans une fourchette de prix de $ 1,36 à $ 2,56.

Arch Biopartners compte actuellement 62 598 000 actions en circulation. La capitalisation boursière d'Arch Biopartners est de $121,44 million. Arch Biopartners a un ratio cours/bénéfice (ratio PE) de -37.66.

ARCH Dernières nouvelles

Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing have begun...

Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private placement...

Closes Units for Debt Settlement

TORONTO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has closed a transaction that...

Units for Debt Settlement

TORONTO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has arranged a transaction to...

Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

TORONTO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Alberta Health Services (AHS) has approved...

Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins

Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI)Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its...

Arch Biopartners Closes Non-Brokered Private Placement

TORONTO, July 30, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has closed the non-brokered private placement...

Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, July 29, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private placement...

Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product

TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced that Dalton Pharma Services (Dalton) has completed the...

Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University of Calgary’s Conjoint Health...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.115.820105820111.892.011.71124411.88533891CS
40.042.040816326531.962.011.59147781.83627288CS
120.136.951871657751.872.21.59171421.94108481CS
260.3219.04761904761.682.21.36149151.76180286CS
520.5134.22818791951.492.561.36193581.83235471CS
156-1.42-41.52046783633.424.250.97197032.20066791CS
2601.05110.5263157890.955.30.74270551.99328394CS

ARCH - Frequently Asked Questions (FAQ)

What is the current Arch Biopartners share price?
The current share price of Arch Biopartners is $ 2,00
How many Arch Biopartners shares are in issue?
Arch Biopartners has 62 598 000 shares in issue
What is the market cap of Arch Biopartners?
The market capitalisation of Arch Biopartners is CAD 121,44M
What is the 1 year trading range for Arch Biopartners share price?
Arch Biopartners has traded in the range of $ 1,36 to $ 2,56 during the past year
What is the PE ratio of Arch Biopartners?
The price to earnings ratio of Arch Biopartners is -37,66
What is the cash to sales ratio of Arch Biopartners?
The cash to sales ratio of Arch Biopartners is 63,09
What is the reporting currency for Arch Biopartners?
Arch Biopartners reports financial results in CAD
What is the latest annual turnover for Arch Biopartners?
The latest annual turnover of Arch Biopartners is CAD 1,98M
What is the latest annual profit for Arch Biopartners?
The latest annual profit of Arch Biopartners is CAD -3,33M
What is the registered address of Arch Biopartners?
The registered address for Arch Biopartners is 27 ST. CLAIR AVENUE EAST, P.O. BOX 305, TORONTO, ONTARIO, M5V 1M1
What is the Arch Biopartners website address?
The website address for Arch Biopartners is archbiopartners.com
Which industry sector does Arch Biopartners operate in?
Arch Biopartners operates in the ADVERTISING AGENCIES sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
MUST.HMust Capital Inc
$ 0,06
(200,00%)
165k
KUAI.PKua Investments Inc
$ 0,045
(125,00%)
14k
CRBKCarebook Technologies Inc
$ 0,095
(111,11%)
420,1k
CPLCopper Lake Resources Ltd
$ 0,01
(100,00%)
9k
VKG.HNorse Gold Corp
$ 0,02
(100,00%)
2,16k
TVITVI Pacific Inc
$ 0,005
(-50,00%)
11k
MTBMTB Metals Corp
$ 0,01
(-50,00%)
116,4k
ETUE2gold Inc
$ 0,005
(-50,00%)
10k
KOVOKovo+ Holdings Inc
$ 0,035
(-41,67%)
15k
PORPortofino Resources Inc
$ 0,01
(-33,33%)
349k
MATEBlockmate Ventures Inc
$ 0,41
(38,98%)
9,03M
DMDataMetrex AI Limited
$ 0,005
(0,00%)
4,48M
THRMTherma Bright Inc
$ 0,04
(14,29%)
3,45M
GPUSAlset AI Ventures Inc
$ 0,16
(-3,03%)
2,41M
SSESilver Spruce Resources Inc
$ 0,005
(0,00%)
2,14M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées